Dr. Weber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Duke Medicine Cir
Durham, NC 27710Phone+1 919-668-1367Fax+1 919-668-1366
Education & Training
- Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1993 - 1997
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1989 - 1992
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1989
Certifications & Licensure
- NC State Medical License 1994 - 2025
- PA State Medical License 2002 - 2002
- CT State Medical License 1992 - 1993
- OH State Medical License 1990 - 1992
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 8 citationsLong-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.Thomas J Weber, Erik A Imel, Thomas O Carpenter, Munro Peacock, Anthony A Portale
The Journal of Clinical Endocrinology and Metabolism. 2022-12-17 - 5 citationsEfficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.Maria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, Thomas Carpenter, Hae Il Cheong
Calcified Tissue International. 2022-10-01 - 27 citationsDiagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience.Kathryn Dahir, María Belén Zanchetta, Irinel Stanciu, Cemre Robinson, Janet Y. Lee
Journal of the Endocrine Society. 2021-09-01
Journal Articles
- A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults with X‐Linked Hypophosphatemia: W...Thomas Weber, Mary D Ruppe, Anthony A Portale, Erik A Imel, Thomas O Carpenter, Karl L Insogna, Farzana Perwad, Pisit Pitukcheewanont, Journal of Bone and Mineral Research
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: